$0.22 EPS Expected for Sucampo Pharmaceuticals, Inc. (SCMP) This Quarter
Analysts expect Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to report earnings per share (EPS) of $0.22 for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Sucampo Pharmaceuticals’ earnings. Sucampo Pharmaceuticals posted earnings of $0.23 per share in the same quarter last year, which indicates a negative year over year growth rate of 4.3%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, August 2nd.
According to Zacks, analysts expect that Sucampo Pharmaceuticals will report full year earnings of $1.01 per share for the current fiscal year. For the next year, analysts expect that the business will post earnings of $1.04 per share. Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Sucampo Pharmaceuticals.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings results on Wednesday, May 3rd. The biopharmaceutical company reported $0.23 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by $0.05. Sucampo Pharmaceuticals had a net margin of 11.36% and a return on equity of 43.27%. The firm had revenue of $56.30 million for the quarter, compared to analysts’ expectations of $54.15 million. During the same period in the prior year, the company earned $0.21 EPS. The firm’s quarterly revenue was up 19.3% on a year-over-year basis.
A number of research firms have recently issued reports on SCMP. Jefferies Group LLC dropped their price target on Sucampo Pharmaceuticals from $14.00 to $13.00 and set a “buy” rating on the stock in a research note on Friday, March 17th. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 4th. ValuEngine upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Maxim Group restated a “buy” rating and issued a $21.00 price target on shares of Sucampo Pharmaceuticals in a research note on Thursday, April 13th. Finally, Mizuho restated a “buy” rating and issued a $14.00 price target on shares of Sucampo Pharmaceuticals in a research note on Tuesday, April 4th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Sucampo Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $16.71.
Shares of Sucampo Pharmaceuticals (NASDAQ SCMP) traded up 1.40% on Wednesday, hitting $10.85. The stock had a trading volume of 465,544 shares. The stock has a 50 day moving average of $10.28 and a 200-day moving average of $11.25. The stock has a market cap of $504.13 million, a PE ratio of 18.08 and a beta of 1.46. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $17.55.
Large investors have recently modified their holdings of the company. Russell Investments Group Ltd. bought a new stake in shares of Sucampo Pharmaceuticals during the fourth quarter valued at $555,000. State Street Corp raised its position in shares of Sucampo Pharmaceuticals by 32.9% in the fourth quarter. State Street Corp now owns 581,835 shares of the biopharmaceutical company’s stock valued at $7,882,000 after buying an additional 143,906 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Sucampo Pharmaceuticals by 7.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,559,433 shares of the biopharmaceutical company’s stock valued at $21,130,000 after buying an additional 103,986 shares during the period. Envestnet Asset Management Inc. acquired a new position in shares of Sucampo Pharmaceuticals during the fourth quarter valued at about $115,000. Finally, A.R.T. Advisors LLC acquired a new position in shares of Sucampo Pharmaceuticals during the fourth quarter valued at about $233,000. 57.00% of the stock is currently owned by hedge funds and other institutional investors.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.